Hikma Pharmaceuticals' (HIK) Overweight Rating Reaffirmed at JPMorgan Chase & Co.

Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research note issued on Friday, MarketBeat reports.

Separately, Berenberg Bank increased their target price on shares of Hikma Pharmaceuticals from GBX 2,400 ($31.02) to GBX 2,560 ($33.09) and gave the stock a "buy" rating in a report on Wednesday, January 29th.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock traded down GBX 5.65 ($0.07) on Friday, hitting GBX 2,118 ($27.38). 611,446 shares of the stock traded hands, compared to its average volume of 2,152,808. The company's fifty day moving average is GBX 2,170.52 and its 200 day moving average is GBX 2,012.72. Hikma Pharmaceuticals has a 1-year low of GBX 1,750 ($22.62) and a 1-year high of GBX 2,360 ($30.51). The company has a market capitalization of £5.87 billion, a PE ratio of 20.78, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.